EHA 2024 preview – Shattuck has a heart scare
An early study of the group’s anti-CD47 project SL-172154 has seen waning efficacy, a heart attack and a death.
An early study of the group’s anti-CD47 project SL-172154 has seen waning efficacy, a heart attack and a death.
The company’s long-delayed pivotal trial is hit by a stronger-than-expected placebo performance.
The company reckons its tech could solve problems with current ADCs, but the market isn’t giving it much credit yet.
The company makes no secret of the need for durability with its anti-CD47 project SL-172154.
Komet-007 showed no differentiation syndrome, but the group didn’t disclose data on menin inhibitor-experienced patients.
Can a combination approach improve the efficacy of ziftomenib in AML patients with KMT2A rearrangements?